Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Craig Wilkes

Podiatrist, Foot & Ankle Surgery Rocklin, CA Doctor of Podiatric Medicine

NPI 1942321138 CMS profile 133144

6000 Fairway Dr, Ste 18, Rocklin, CA 95677

Open in the dashboard

General payments

$40,415

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Craig Wilkes of Rocklin, CA is reported in the CMS Open Payments database as having received $40,415 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,058 40
2024 General $3,228 39
2023 General $4,948 48
2022 General $8,008 48
2021 General $10,828 59
2020 General $1,581 14
2019 General $9,765 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Craig Wilkes
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Craig Wilkes were reported at $2,058. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Craig Wilkes Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $9,765 $389 $118–$1,406 $163
2020 $1,581 $191 $62–$691 $114
2021 $10,828 $329 $104–$1,341 $132
2022 $8,008 $419 $125–$1,611 $149
2023 $4,948 $377 $128–$1,164 $160
2024 $3,228 $394 $134–$1,168 $164
2025 $2,058 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $22,504 120 payments
  2. Sequoia Surgical, Inc. $5,280 15 payments
  3. Evolution Surgical, Inc $4,929 18 payments
  4. Treace Medical Concepts, Inc. $3,738 29 payments
  5. TissueTech, Inc. $704 27 payments
  6. Stryker Corporation $580 5 payments
  7. Bioventus LLC $442 8 payments
  8. Smith+Nephew, Inc. $368 10 payments
  9. Alafair Biosciences,Inc. $272 3 payments
  10. Orthofix Medical, Inc. $175 9 payments
  11. Other $1,422 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $19,153 19 payments
  2. Travel and Lodging $11,618 40 payments
  3. Food and Beverage $9,644 236 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM Foot And Ankle $1,786 10 payments
  2. Lapiplasty System Y $1,717 12 payments
  3. NEOX $628 24 payments
  4. CLARIX $628 24 payments
  5. VersaWrap $272 3 payments
  6. Physio-Stim $205 11 payments
  7. Exogen $189 5 payments
  8. ACTISHIELD $173 1 payment
  9. PERCUPLASTY TRAY $165 4 payments
  10. ORTHOLOC 2 LAPIFUSE $163 1 payment
  11. Other $3,332 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

209

Median for Podiatry: 160

Drug cost

$1,946

Median for Podiatry: $2,368

Branded share of claims

25.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Terbinafine Hcl Generic 61 $482
Clobetasol Propionate Generic 12 $338
Clotrimazole Generic 16 $288
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 31 $264
Cephalexin Generic 40 $236
Nabumetone Generic 14 $214
Silver Sulfadiazine Generic 12 $45
Ssd Silver Sulfadiazine Brand 11 $44
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$81,049

Of which drugs: $260

Medicare patients

246

Average age 72

Services billed

1,657

156 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 64%
High blood pressure 58%
Depression 19%
Osteoporosis 18%
Diabetes 17%
Ischemic heart disease 14%
Cancer 13%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 63 331 $230
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 63 369 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $51
$51 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record